Exchange: NASDAQ·Updated 05:16 PM EST

RYTM Earnings

Latest Earnings Results: Q3 '26

Reported: Nov 03

Estimated EPS

-$0.71

Reported EPS

-$0.61

Surprise

+14.05%

Estimated Rev

$85.57M

Reported Rev

$92.13M

Surprise

+7.67%

• Reported GAAP EPS of -$0.61 up 25.61% YoY • Reported revenue of $92.13M up 79.59% YoY • For 2026, Rhythm Pharmaceuticals anticipates approximately $360M to $380M in Non-GAAP Operating Expenses, including R&D expenses of approximately $165M to $175M and SG&A expenses of approximately $195M to $205M.

Generated by Stocktwits using AI and company-reported earnings data for Q3 '26. This recap is intended to help readers understand the quarter quickly. Verify key figures in the linked source materials; the summary may contain errors and is not investment advice.

Investor Presentation10-Q

Historical Earnings

Quarterly

Annual

EPS

Revenue

Fiscal PeriodEstimatedReportedSurpriseResult
Q4 '26
-$2.84
--
--
N/A
Q3 '26
-$0.71
-$0.61
14.05%
BEAT
Q2 '26
-$0.81
-$0.73
9.56%
BEAT
Q1 '26
-$0.82
-$0.83
-0.61%
MISSED
Q4 '25
-$0.80
-$0.73
9.26%
BEAT

Advertisement|Remove ads.